No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

Earlens Announces Partnership with Verily

Companies to Develop Next-Generation Capabilities for Earlens® Contact Hearing Solution

Editor: What To Know

  • While some acoustic hearing aids have announced new AI capabilities and overall wellness benefits, they are typically only worn for part of the day, while the Lens in the Earlens solution remains in the ear at all times.
  • “Earlens is the only hearing solution that places a lens on the eardrum, and by combining our innovative medical, wearable and sensor technologies, we can further revolutionize the industry to support patients dealing with hearing challenges.
  • A major factor in the underutilization of hearing aids is disappointment with the quality and clarity of sound that conventional hearing devices, like acoustic hearing aids and amplifiers, provide.

June 13, 2020

Earlens announced they have entered into a strategic agreement with Verily, an Alphabet company, to develop next-generation capabilities for the Earlens® Contact Hearing Solution.

According to the Hearing Loss Association of America, about 20 percent of Americans, or 48 million people, report some degree of hearing loss. Yet, research estimates that only 1 in 5 individuals who might benefit from treatment seek help. A major factor in the underutilization of hearing aids is disappointment with the quality and clarity of sound that conventional hearing devices, like acoustic hearing aids and amplifiers, provide. Earlens has developed a novel way to overcome these sound quality limitations by creating sound without an acoustic signal.

“Unlike traditional hearing aids that amplify sound through a speaker, Earlens uses a small lens to vibrate the eardrum, which directly activates the natural hearing process and delivers the broadest bandwidth available today,” said Bill Facteau, Earlens president and chief executive officer. “By combining our complementary sets of expertise, we aim to develop a next-generation hearing solution, as well as explore modalities for monitoring that may address conditions beyond hearing loss.”

Earlens believes Verily’s capabilities make Verily a natural partner as Earlens expands the capabilities and impact of its solutions. While some acoustic hearing aids have announced new AI capabilities and overall wellness benefits, they are typically only worn for part of the day, while the Lens in the Earlens solution remains in the ear at all times.

“Verily’s extensive experience in custom miniaturized, low-power and integrated medical devices uniquely position us to enhance the Earlens solution with a smaller, more efficient and more powerful behind-the-ear device,” said Brian Otis, chief technical officer, Verily. “Earlens is the only hearing solution that places a lens on the eardrum, and by combining our innovative medical, wearable and sensor technologies, we can further revolutionize the industry to support patients dealing with hearing challenges.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy